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Natural products derived from the secondary metabolism of microbes 
constitute a cornerstone of modern medi-
cine. Engineering bugs to produce these 
products in high quantities is a major 
challenge for biotechnology, which has 
usually been tackled by either one of two 
strategies: iterative random mutagenesis 
or rational design. Recently, we analyzed 
the transcriptome of a Streptomyces cla-
vuligerus strain optimized for production 
of the β-lactamase inhibitor clavulanic 
acid by multiple rounds of mutagenesis 
and selection, and discovered that the 
observed changes matched surprisingly 
well with simple changes that have been 
introduced into these strains by rational 
engineering. Here, we discuss how in the 
new field of synthetic biology, random 
mutagenesis and rational engineering 
can be implemented complementarily in 
ways which may enable one to go beyond 
the status quo that has now been reached 
by each method independently.
In our recent paper in Microbial 
Biotechnology,1 we compared levels of 
gene expression between a Streptomyces 
clavuligerus clavulanic acid overproduc-
tion mutant (DS48802) and the wild-
type. The changes caused by random 
mutagenesis were strikingly similar to 
those rationally engineered by two strate-
gies that have recently been employed to 
increase clavulanic acid production in S. 
clavuligerus: redirection of carbon fluxes 
towards the key clavulanic acid precur-
sor glyceraldehyde-3-phosphate (G3P)2 
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and upregulation of pathway-specific 
activators.3,4 More precisely, we found the 
pathway-specific activator genes ccaR and 
claR to be more highly expressed in strain 
DS48802, and we also observed changes 
in transcript levels of genes associated with 
glycolysis and the citric acid cycle, which 
appear to match the intended effect of the 
recently engineered gap1 deletion mutant, 
leading to a redirection of carbon fluxes 
towards G3P. A third way in which over-
production of chemicals has been achieved 
by rational engineering is the genomic 
duplication or even amplification of the 
biosynthetic gene cluster. Such changes 
have recently been successfully imple-
mented for overproduction of platensimy-
cin5 and nikkomycin.6 Although a similar 
amplification has been observed previ-
ously in a randomly mutagenized kana-
mycin overproduction strain,7 we did not 
observe any amplification of the clavulanic 
acid biosynthetic gene cluster on genomic 
DNA hybridizations to our microarrays. 
However, the observed overexpression of 
the clavams biosynthetic gene clusters—
which are strongly related to the clavulanic 
acid gene cluster—in strain DS48802 may 
also point to recruitment of enzymes for 
clavulanic acid overproduction from these 
homologous pathways, alleviating the 
need for amplification of the original gene 
cluster. Even though in this case it would 
be an enigma why cvm5 and cvm6p, which 
are thought to be specifically involved in 
the final steps of 5S clavam biosynthe-
sis,8,9 are also overexpressed in DS48802, 
the general picture shows that random 
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bottleneck reactions that may have been 
missed in the earlier model-driven engi-
neering (Fig. 1).
When envisaging a Streptomyces 
host for synthetic biology, many efforts 
have been focussed on generating a 
minimal Streptomyces genome. For 
example, Komatsu et al.11 recently engi-
neered a genome-minimized genome of 
Streptomyces avermitilis, by deleting large 
regions from the chromosomal termini. 
Metabolic modeling may also aid in guid-
ing the construction of such a minimal 
streptomycete, by predicting the minimal 
set of metabolic genes necessary for pro-
duction of biomass. Recently, we used in 
silico knockouts in a Streptomyces clavu-
ligerus genome-scale metabolic model to 
predict that the 1.8-Mb linear plasmid 
that the strain possesses is not required 
for primary metabolism and could poten-
tially be cured from the strain.12 We used 
the same model—the version published by 
Medema et al.12 available from the authors 
in SBML format upon request—to 
much more difficult. This is where ran-
dom mutagenesis can come in, again to 
find a local optimum, but this time an 
optimum which may be much closer to 
the global optimum because the rest of 
the metabolic and regulatory network has 
first been radically modified.
As genome sequencing is becoming 
cheaper by the day, an interesting possi-
bility would be to expose the first version 
of a design for an overproduction strain 
to one or a few rounds of mutagenesis, 
and subsequently sequence the genomes 
and transcriptomes of a range of promis-
ing mutants. In this way, mutations that 
can help optimize the first design may be 
identified and combined together without 
the need for long and tedious repetitions 
of such rounds of mutagenesis. Metabolic 
modeling can sometimes aid in the selec-
tion of the mutations from the modi-
fied genomes, by predicting whether the 
changes will lead to higher production 
of the compound. And conversely, the 
observed profile of mutations can pinpoint 
mutagenesis and traditional engineering 
yield similar results: small adjustments 
to the metabolic or regulatory network of 
the cell which allow finding a local opti-
mum of production given the rest of the 
network.
As the field of synthetic biology is 
maturing, the methodologies for ratio-
nally engineering bacterial strains for 
production of natural products are dras-
tically changing.10 With these changes 
come new prospects to make random 
mutagenesis approaches complement 
rational engineering in novel ways, in 
a ‘next generation’ synthetic biology 
approach. Synthetic biology engineer-
ing is by definition not restricted to the 
natural architecture of a certain bacte-
rial strain: cellular systems can be exten-
sively re-engineered, or even engineered 
from the ground up in a de novo fashion. 
But while the general biological knowl-
edge necessary for major re-engineering 
is often available, the fine-tuning of a 
design up to the nucleotide level is often 
Figure 1. Comparison of several approaches for strain optimization. (A) In traditional random mutagenesis, the strain is subjected to several iterations 
of mutagenesis and screening, in an attempt to arrive at a higher-producing phenotype. (B) In the basic synthetic biology approach, an advantage is 
gained by intelligently engineering a high-producer strain. The strain is designed, engineered and an activity screen is performed to test the obtained 
production titers. (C) Proposed pipeline for compound production optimization based on a synergy of synthetic biology, systems biology and random 
mutagenesis. After initial engineering of a first design and screening of its productivity, a round of random mutagenesis of the resulting “designer bug 
version 1.0” follows. The mutants are screened and promising improved mutants are s le t d for genome sequencing. The identified mutations are 
tested, when possible, with genome-scale metabolic modeling and combined in engineering a second version of the designer bug. Several additional 
iterations of design updates or ‘bug fixes’, mutagenesis and genome sequencing may follow to further optimize the production titers.
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gap-filled this reduced model by re-add-
ing 49 enzymes, which connect essen-
tial enzymes with conditionally essential 
enzymes, from the set of 194 enzymes 
that were left from the previous analy-
sis. This successfully allowed simulation 
of biomass production again. In the end, 
we identified a set of 145 enzymes (29%, 
Sup. Table 1) which were predicted to be 
nonessential. These enzymes are encoded 
by 195 chromosomally encoded genes and 
20 plasmid-encoded genes which could 
potentially be deleted from the S. clavu-
ligerus genome in order to minimize it. 
As the core chromosome of S. clavuligerus 
is already significantly smaller (6.8 Mb) 
than the recently published genome-min-
imized S. avermitilis chromosome (7.6 
Mb),11 the prospect of being able to fur-
ther minimize the genome is enthralling. 
It should be kept in mind that these results 
were obtained from the analysis of only a 
fraction of the total 7,281 annotated genes 
from the S. clavuligerus genome (i.e., those 
that encode enzymes). Visualization of 
the predicted essential and nonessential 
(enzymes) from the network one by one, 
and checked the cellular growth again by 
performing flux balance analysis.14 Of the 
1,079 pairs of enzymes, 657 (61%) were 
predicted to be essential for biomass pro-
duction. Seventy enzymes which were not 
essential according to the first analysis 
appeared to be essential when knocked out 
as part of a pair, and were therefore labeled 
as conditionally essential. Subsequently, 
we performed triple knockouts by remov-
ing three directly connected enzymes at a 
time. Nineteen new conditionally essential 
enzymes were detected from this round of 
knockouts. In total, 194 enzymes (38%) 
were found nonessential after these three 
rounds of in silico knockouts. However, 
after removing these 194 predicted non-
essential enzymes from the genome-scale 
model, the model of the cell was not viable 
during flux balance analysis, probably 
because in a few cases the conditionality 
exists on an even higher level, e.g., when 
there exist two entire entirely indepen-
dent alternative pathways of which at least 
one is necessary. Therefore, we manually 
interpret the expression changes seen in 
the optimized strain1, and again using flux 
balance analysis on in silico knockouts in 
a minimal medium, we have now attained 
a first approximation of the minimal S. 
clavuligerus genome. As a start, we gener-
ated in silico knockouts of all 507 unique 
enzymes (from 1115 EC-annotated 
enzymes in total) in the S. clavuligerus 
genome-scale metabolic model. For 159 
knockouts (31%), the model was unable 
to simulate biomass production anymore; 
the 159 enzymes linked to these knock-
outs were therefore labeled as uncondi-
tionally essential. To be able to identify 
conditionally essential enzymes as well, 
we subsequently generated a metabolic 
network13 which links enzyme nodes via 
edges based on shared common metabo-
lites. Highly connected metabolites were 
removed from the model reactions, as well 
as reactions which contain one of these 
highly connected metabolites as their only 
product or substrate. We then performed 
double knockouts by removing all pos-
sible pairs of directly connected nodes 
Figure 2. Visualization of essential and nonessential enzymes on the KEGG global pathway map, constructed using the iPATH 2 web server.15 Reactions 
catalyzed by predicted essential enzymes are colored in red, reactions catalyzed by predicted non-essential enzymes are colored in green.
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